

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/807,665	06/28/2001	Carlos F. Barbas	TSRI 645.1	2213
26621	7590 03/09/2005		EXAMINER	
	PPS RESEARCH INST	CARLSON, KAREN C		
	PATENT COUNSEL, TI TH TORREY PINES RO	ART UNIT	PAPER NUMBER	
LA JOLLA,	CA 92037		1653	
			DATE MAILED: 03/09/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
		09/807,665	BARBAS, CARLOS F.					
	Office Action Summary	Examiner	Art Unit					
		Karen Cochrane Carlson, Ph.D.	1653					
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE - Exte - after - if the - if NC - Failt Any - earn	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be tire within the statutory minimum of thirty (30) day rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered time the mailing date of this c (35 U.S.C. § 133).					
Status								
1)⊠	Responsive to communication(s) filed on <u>December 13, 2004</u> .							
2a)⊠	This action is <b>FINAL</b> . 2b) ☐ This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
4)⊠	I)⊠ Claim(s) <u>1 and 22-37</u> is/are pending in the application.							
	4a) Of the above claim(s) 22-37 is/are withdrawn from consideration.							
·	Claim(s) is/are allowed.							
·	Claim(s) <u>1</u> is/are rejected.							
·	Claim(s) is/are objected to.		•					
•	Claim(s) are subject to restriction and/or	relection requirement.						
Applicat	ion Papers							
•	9) The specification is objected to by the Examiner.							
10)	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
44)[7]	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  1) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
اــا(۱۱	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action of form P	10-152.				
Priority (	ınder 35 U.S.C. § 119							
	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priority documents  Application from the leternational Russian	s have been received. s have been received in Applicati ity documents have been receive	ion No	Stage				
* 0	application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
•	see the attached detailed Office action for a list	or the certified copies not receive		·				
Attachmen	t(s)							
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)								
3) 🔲 Infor	e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) er No(s)/Mail Date	Paper No(s)/Mail Double of Informal F		O-152)				
	•		<u> </u>					

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) Application/Control Number: 09/807,665

Art Unit: 1653

This Office Action is in response to the amendment filed on December 13, 2004. Claims 2-21 have been canceled. Claims 1 and 22-37 are currently pending.

Applicant's election with traverse of Invention 41, SEQ ID NO: 41 in the paper filed March 8, 2004 was acknowledged and searched in the first action on the merits (ie, the previous Office Action). The traversal was on the ground(s) that Applicants urged that the sequences listed in previously amended Claim 1 are unified by the structure RSDXLV(R/K). It was noted that the amino acid sequence of elected SEQ ID NO: 41 is KSADLKR and does not share this structural sequence. Therefore, the argument that there is a single structure to be searched for all of the sequences listed in previously amended Claim 1 was not considered to be persuasive. The polynucleotide encoding SEQ ID NO: 41 was rejoined because search of the polypeptide resulted in art for the encoding polynucleotide and therefore did not pose an undue burden on the Examiner.

New Claims 22-37 are drawn to zinc finger proteins comprising 2-12 different nucleotide binding regions selected from SEQ ID NOs: 1-110. Only SEQ ID NO: 41 was searched in the previous Office Action. Therefore, new Claims 22-37 are withdrawn from further consideration because these claims are drawn to non-elected inventions. Thus, only Claim 1 is currently under examination.

The Office does not have the resources to search 110 unrelated sequences. It would take days just to accomplish and electronic sequence search of the databases. It would take days for the Examiner to review the sequence searches and correlate art for such a claim. Thus, it would take well over a week of uninterrupted time to arrive at a first action on the merits. It would have been helpful to Applicants and the Examiner if a few consensus sequences had been provided, each representing specific sequences, to ease the search burden. However, in those circumstances, it would be understood that the consensus sequence represents all sequences designated by Applicants and if the consensus sequence were found then all

sequences represented thereby would be considered to be obvious variants of each other and rejected accordingly.

The IDS filed April 77, 2002 did not have a PTO-1449 attached, or references attached.

Applicants argue that a PTO 1449 was attached to this IDS. As noted, it is not in the file.

Please replace the PTO 1449.

Priority is set to **October 16**, **1998**. The Examiner apologizes for the error in the year for priority as stated in the previous Office Action.

## Withdrawal of Rejections

The rejection of Claims 1-19 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 28-56 of U.S. Patent No. 6,242,568 is withdrawn.

The rejection of Claims 1-13 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-3, 5-39, 53 of U.S. Patent No. 6,140,466 is withdrawn.

The rejection of Claims 20 and 21 under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, is withdrawn.

The rejection of Claims 1-21 under 35 U.S.C. 112, second paragraph, is withdrawn.

The rejection of Claims 2-7 and 14-22 under 35 U.S.C. 103(a) as being unpatentable over Barbas et al. (USP 6,242,568, issued June 5, 2001 and having a 102(e) date of December 30, 1996), is withdrawn.

## **Maintenance of Rejections**

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claim 1 is again rejected under 35 U.S.C. 102(e) as being anticipated by Barbas et al. (USP 6,242,568, issued June 5, 2001 and having a 102(e) date of December 30, 1996).

Barbas et al. teach C7 zinc finger nucleotide binding polypeptide containing instant SEQ ID NO: 41 (KSADLKR) in Figure 15 and in patent SEQ ID NO: 42 at amino acids 20-26 (Claim 1).

USP 6,140,466 (priority to at least May 27, 1997) is the same up through Example 13 of USP 6,242,568 and would be applied in the same manner as 6,242,568.

At page 8 of their response, Applicants argue that '568 does not teach or suggested an isolated polypeptide that consists essentially of SEQ ID NO: 41. It is not clear why Applicants state this when there are at least 3 regions comprising SEQ ID NO: 41 in the amino acid sequence shown in Figure 15 alone. The phrase "consisting essentially of" is open language, and therefore this rejection stands.

No Claims are allowed.

Application/Control Number: 09/807,665 Page 5

Art Unit: 1653

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 571-272-0946. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMENER

Karen Cachane Carkon Par